Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
← catalyst calendarSponsored by Gain Therapeutics, Inc. (industry) · GANX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
7
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-21 | actual | When the study began enrolling |
| Primary completion | 2025-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson Disease
Intervention
- Drug: GT-02287
Primary outcomes
what the primary-completion date above is the date OFIncidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs)
measured From first dose to Day 105
Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)
measured From first dose to Day 105
Permalink · GANX's whole pipeline · Catalyst calendar · Every registered study · What changed